Drug Profile


Alternative Names: APB-231-A2; SK&F 99085; SR-45023A; SR-9223i

Latest Information Update: 04 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator
  • Class Antineoplastics; Bisphosphonates; Osteoporosis therapies
  • Mechanism of Action Antioxidants; Apoptosis stimulants; Farnesoid X-activated receptor modulators; HMG-CoA reductase inhibitors; Osteoclast inhibitors; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Breast cancer; Cancer metastases; Hypercholesterolaemia; Malignant melanoma; Ovarian cancer; Postmenopausal osteoporosis; Prostate cancer

Most Recent Events

  • 04 Feb 2008 Discontinued - Phase-I/II for Postmenopausal osteoporosis treatment in USA (PO)
  • 29 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation
  • 12 Mar 2004 Discontinued - Phase-I for Cancer metastases in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top